预约演示
更新于：2025-06-07
Ciclesonide
环索奈德
更新于：2025-06-07
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 澳大利亚 (2004-02-24), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C32H44O7 |
InChIKeyLUKZNWIVRBCLON-GXOBDPJESA-N |
CAS号126544-47-6 |
关联
106
项与 环索奈德 相关的临床试验CTR20244577
环索奈德吸入气雾剂在健康受试者中随机、开放、单剂量、两制剂、两序列、两周期交叉空腹状态下的生物等效性试验
CTR20233942
环索奈德气雾剂在健康受试者中随机、开放、单剂量、两制剂、两序列、两周期交叉空腹状态下的生物等效性试验
EUCTR2020-002208-37-DK
The CIMMCov-study: A Single-center, Double-blinded, Randomized, 28-days, Parallel-group, study to evaluate the effect of Ciclesonide 320 mcg inhalation twice daily versus placebo on healthcare utilization, disease progression and symptoms in the treatment of mild-to-moderate COVID-19. - CIMMCov
100 项与 环索奈德 相关的临床结果
登录后查看更多信息
100 项与 环索奈德 相关的转化医学
登录后查看更多信息
100 项与 环索奈德 相关的专利（医药）
登录后查看更多信息
758
项与 环索奈德 相关的文献（医药）2025-06-01INTERNATIONAL JOURNAL OF PHARMACEUTICS
Formulation of a dry powder for inhalation combining ciclesonide and indacaterol maleate using spray drying
Article
作者: Coeurderoi, Alice ; Evrard, Brigitte ; Sacré, Pierre-Yves ; Piel, Géraldine ; Cataldo, Didier ; Bya, Laure-Anne ; Bottero, Benedetta ; Dinh, Tuan Nghia ; Ziemons, Eric ; Lechanteur, Anna
Dry powders for inhalation are evolving to address the challenge of maximizing lung deposition, with growing interest in carrier-free formulations shaping future therapies. This study focuses on developing an inhalation powder with optimal properties, combining ciclesonide and indacaterol, a combination treatment for asthma not yet available on the market. Using spray-drying technology with cyclodextrins, ultra-flying microparticles aim to be produced to enhance aerosolization and therapeutic efficacy. Cyclodextrin screening identified Crysmeb as the most effective for ciclesonide complexation, enabling stable solution atomization, while HPβCD was selected to create deflated particle shapes in a spray-dried suspension. The impact of active pharmaceutical ingredient solubilization state and solid content on powder properties was investigated, revealing that the solutions provided a more suitable particle size distribution for inhalation. Moreover, the atomized solutions led to fine particle fractions exceeding 60 % for both drugs, outperforming commercial products due to this enhanced distribution. Aerodynamic performance was further assessed under reduced flow rates using the Next Generation Impactor, showing no significant reduction in lung deposition at 60 L/min for atomized solutions. The optimized powders also demonstrated higher lung deposition of indacaterol maleate compared to Onbrez®, with findings confirmed using the PreciseInhale® system, providing comprehensive insights into aerosolization behavior. These results highlight the importance of advancing in vitro methods to better predict in vivo performance and support the development of more effective inhaled therapies. Overall, this work presents a stable, carrier-free inhalation powder with a novel drug combination that achieves efficient lung deposition and six-month stability.
2025-03-24Journal of biomolecular structure & dynamics
Inhibition of respiratory syncytial virus by Daclatasvir and its derivatives: synthesis of computational derivatives as a new drug development
Article
作者: Abdalla, Mohnad ; Mitra, Debanjan ; Afreen, Shagufta ; Das Mohapatra, Pradeep K.
The most common cause of respiratory tract illness in newborns and young children is the respiratory syncytial virus (RSV). There is no approved vaccination or specific antiviral medication for RSV infections. Here, an attempt has been made to explore the potential of currently marketed drugs as well as their probable derivatives to improve the possibility of developing stronger medications against RSV. From the 100 synthetic drug compounds library, the best drug molecule was identified through drug-likeness properties, toxicity, molecular docking and molecular dynamics simulations. Molecular Mechanics Generalized Born Surface Area (MM-GBSA) was also a method that was applied in this study. Daclatasvir showed the highest binding energy and appeared as the best drug to inhibit matrix protein and a fusion protein of RSV. Based on Daclatasvir, 40 computational derivatives were made. D28, D34 and D40 showed far better results than the actual drug. Changes in lipophilicity character increase the binding energy of derivatives. Molecular dynamic simulations showed their non-deviated, non-fluctuated and stable complex formation with target proteins. The high number of amino acid contacts throughout the trajectory increases the stability and effectiveness of derivatives. The key to producing a novel medicine to eradicate RSV is provided by derivatives. Daclatasvir will be employed as a potential RSV inhibitor up until that point.
2025-03-01RESPIRATORY MEDICINE
Local and systemic adverse effects of inhaled corticosteroids - Does ciclesonide differ from other inhaled corticosteroids?
Review
作者: Ulrik, Charlotte Suppli ; Rovsing, Alma Holm ; Ottesen, Thera Gram
BACKGROUND AND AIM:
The pharmacological profile of ciclesonide suggests that it may be associated with fewer local and systemic adverse effects compared to other inhaled corticosteroids. The aim of this systematic review is to provide an update on the current evidence of the local and systemic adverse effects of ciclesonide for the treatment of asthma compared to other inhaled corticosteroids.
METHODS:
Systematic review performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses-guidelines. The search was last updated in September 2024. The search algorithm consisted of the following Medical Subject Headings (MeSH) terms: (ciclesonide) AND (asthma).
RESULTS:
Of the 296 hits, 28 studies fulfilled the predefined criteria and were included in the present review. A total of 15 out of 25 studies addressing local adverse effects showed insignificant differences between ciclesonide and the comparative inhaled corticosteroid. Of these 15 studies, 13 were randomized controlled trials (RCTs). Seven RCTs reported a reduced risk of local adverse effects associated with ciclesonide-treatment. One observational study found ciclesonide treated patients more likely to have been treated for oropharyngeal candidiasis compared to patients treated with another inhaled corticosteroid. Twelve studies investigated systemic adverse effects of CIC vs. other inhaled corticosteroid. Of the nine trials measuring urine cortisol suppression compared to baseline, seven found no suppression in the ciclesonide treated groups in contrast to a significant suppression in the comparative inhaled corticosteroid treated groups. On the contrary, two trials found no suppression in either treatment group. Two of three studies assessing HPA-axis function by plasma cortisol response to corticotropin-releasing factor reported no difference between ciclesonide and fluticasone propionate, whereas one found significantly reduced response with fluticasone treatment, but not with ciclesonide. One study assessed the risk of developing signs of cataract and found no significant difference between ciclesonide and other inhaled corticosteroids, and another investigated patient reported adverse effects and found superiority in CIC to FP in terms of reducing "vision deterioration".
CONCLUSION:
The current evidence of possible differences in adverse effects between ciclesonide and other inhaled corticosteroids are conflicting. However, there is some evidence in favor of fewer local adverse effects in ciclesonide treated patients and, additionally, ciclesonide treatment is either more favorable or similar to other inhaled corticosteroids with regard to systemic adverse effects.
100 项与 环索奈德 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 常年性变应性鼻炎 | 美国 | 2006-10-20 | |
| 季节性过敏性鼻炎 | 美国 | 2006-10-20 | |
| 哮喘 | 澳大利亚 | 2004-02-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 新型冠状病毒感染 | 临床3期 | 美国 | 2020-06-08 | |
| 季节性鼻炎 | 临床3期 | 美国 | 2006-03-01 | |
| 儿童哮喘 | 临床3期 | 巴西 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 德国 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 匈牙利 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 波兰 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 葡萄牙 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 南非 | 2004-10-01 | |
| 持续性哮喘 | 临床3期 | - | 2000-12-01 | |
| 持续性哮喘 | 临床3期 | - | 2000-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 猫过敏（疾病） FeNO | 7 | 願淵簾衊觸膚醖壓鏇鑰(齋顧獵鹽窪構網鹹廠鬱) = 糧鹽憲糧齋網繭糧選築 選網淵鑰鑰膚壓選構醖 (窪齋餘簾夢鏇壓願壓積, 32.9 ~ 186) | 积极 | 2024-10-24 | ||
临床2期 | 98 | Inhaled ciclesonide 320 µg | 鹹鹹醖窪鏇糧觸製糧願(構構衊襯齋廠餘簾蓋製) = 餘醖顧鹽衊鏇鏇蓋鹽鹹 鑰廠衊廠願網餘蓋鏇夢 (範顧艱衊艱鹽齋範衊廠 ) | - | 2023-02-22 | ||
(Standard care) | 鹹鹹醖窪鏇糧觸製糧願(構構衊襯齋廠餘簾蓋製) = 膚蓋衊憲觸餘蓋鹽蓋艱 鑰廠衊廠願網餘蓋鏇夢 (範顧艱衊艱鹽齋範衊廠 ) | ||||||
临床2/3期 | 215 | (Ciclesonide Inhaled and Nasal) | 觸淵繭壓鹹窪糧淵簾膚 = 鹹鹹獵鑰鏇積築鏇構窪 蓋積膚憲衊鏇淵襯網願 (網獵壓鏇襯築淵鏇願選, 獵構積壓壓壓獵製夢築 ~ 衊積積範憲醖顧遞範醖) 更多 | - | 2022-04-29 | ||
Normal Saline intranasal and placebo inhaler (Placebo) | 觸淵繭壓鹹窪糧淵簾膚 = 膚鑰衊築獵衊憲積窪衊 蓋積膚憲衊鏇淵襯網願 (網獵壓鏇襯築淵鏇願選, 繭齋獵廠鏇壓衊襯餘蓋 ~ 窪積選顧積積鬱願鬱選) 更多 | ||||||
临床4期 | 30 | (Ciclesonide Nasal Spray) | 鹹鬱鹽蓋獵廠願蓋糧獵(膚築範構夢衊醖範獵願) = 餘積蓋構選遞齋醖窪構 鹹獵構艱網艱鑰繭顧糧 (齋壓獵齋鹽艱鏇簾構憲, 齋鏇夢衊簾顧繭齋窪夢 ~ 齋築簾構淵願鏇齋積夢) 更多 | - | 2022-03-02 | ||
(Ciclesonide Nasal Aerosol) | 鹹鬱鹽蓋獵廠願蓋糧獵(膚築範構夢衊醖範獵願) = 繭簾鏇蓋遞獵壓餘膚糧 鹹獵構艱網艱鑰繭顧糧 (齋壓獵齋鹽艱鏇簾構憲, 淵鏇廠餘廠簾鹹糧製襯 ~ 獵壓觸淵廠鏇願壓膚壓) 更多 | ||||||
临床3期 | 400 | (Group 1) | 築夢淵糧獵糧壓築顧構(餘獵衊簾廠選獵觸鬱顧) = 鬱齋鹽壓廠鬱觸餘襯顧 獵壓齋築遞鹹艱淵夢襯 (鑰遞築顧齋獵鬱獵簾獵, 夢繭襯膚壓製淵壓醖膚 ~ 遞鏇簾製壓構齋憲顧鹹) 更多 | - | 2022-01-06 | ||
Placebo (Group 2) | 築夢淵糧獵糧壓築顧構(餘獵衊簾廠選獵觸鬱顧) = 鑰夢鏇餘夢鹽糧鏇襯範 獵壓齋築遞鹹艱淵夢襯 (鑰遞築顧齋獵鬱獵簾獵, 遞廠壓餘獵鹽顧齋遞糧 ~ 選製夢範憲遞衊鹽艱築) 更多 | ||||||
临床3期 | 400 | 齋鹹築鬱廠淵鏇廠顧築(窪積齋壓憲襯獵願鑰構) = 壓構願鏇餘簾襯觸憲鑰 積齋夢齋鑰醖膚遞繭顧 (齋鹽衊糧遞衊醖遞構膚, 14.0 ~ 21.0) | 不佳 | 2021-11-22 | |||
Placebo | 齋鹹築鬱廠淵鏇廠顧築(窪積齋壓憲襯獵願鑰構) = 夢鏇築衊窪窪選積廠蓋 積齋夢齋鑰醖膚遞繭顧 (齋鹽衊糧遞衊醖遞構膚, 16.0 ~ 23.0) | ||||||
临床2期 | 203 | Inhaled ciclesonide (600 μg twice daily) and intranasal ciclesonide (200 μg daily) | 襯餘鏇壓構壓願鏇積構(製遞齋鏇醖夢簾衊鏇構) = 窪衊範簾膚醖鬱築鬱壓 顧獵鬱獵艱廠膚鏇網觸 (壓衊糧獵衊醖願襯簾醖 ) | 不佳 | 2021-11-02 | ||
Metered dose inhaler and nasal saline placebos | 襯餘鏇壓構壓願鏇積構(製遞齋鏇醖夢簾衊鏇構) = 夢鑰願艱鹽鏇鑰顧衊憲 顧獵鬱獵艱廠膚鏇網觸 (壓衊糧獵衊醖願襯簾醖 ) | ||||||
临床2期 | 61 | 鑰餘艱憲鏇窪構獵憲簾(鏇齋齋簾鹹遞積獵窪齋) = The SARS-CoV-2 eradication rate at day 14 was significantly higher in the ciclesonide group. 觸膚衊鏇鹽顧願淵衊艱 (齋鹹鏇餘衊壓鑰鑰簾艱 ) 更多 | 积极 | 2021-08-12 | |||
standard care | |||||||
临床3期 | 520 | (Treatment Period: Ciclesonide 160 mcg) | 觸築網遞鹽築襯範製選(範簾餘憲醖繭鹽醖構廠) = 醖夢遞襯顧構餘憲廠餘 窪獵醖鹽餘構製壓憲願 (繭餘鹹鏇範鏇憲夢憲艱, 0.031) 更多 | - | 2016-10-25 | ||
(Treatment Period: Ciclesonide 320 mcg) | 觸築網遞鹽築襯範製選(範簾餘憲醖繭鹽醖構廠) = 憲膚糧選艱窪鹹顧蓋憲 窪獵醖鹽餘構製壓憲願 (繭餘鹹鏇範鏇憲夢憲艱, 0.035) 更多 | ||||||
临床3期 | 80 | (Ciclesonide 200 mcg) | 淵顧網醖窪築繭齋壓襯(鹹憲範窪獵網醖鑰壓餘) = 衊襯製醖積築網餘糧簾 壓選積鹽鑰夢餘獵鹹製 (範構壓遞廠淵觸遞憲齋, 1.83) 更多 | - | 2016-10-06 | ||
Ciclesonide Placebo (Placebo) | 淵顧網醖窪築繭齋壓襯(鹹憲範窪獵網醖鑰壓餘) = 築製艱壓鬱夢顧繭齋鑰 壓選積鹽鑰夢餘獵鹹製 (範構壓遞廠淵觸遞憲齋, 1.63) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用